Table 2.
Factors associated with the development of clinical relapse
| Variable | Univariate |
Multivariate |
||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age (years) | 1.026 (0.988-1.066) | 0.177 | ||
| Male (vs. female) | 0.576 (0.254-1.303) | 0.185 | ||
| BMI (kg/m2) | 0.951 (0.808-1.120) | 0.549 | ||
| Diabetes (yes vs. no) | 0.295 (0.040-2.190) | 0.233 | ||
| Hypertension (yes vs. no) | 1.195 (0.407-3.510) | 0.746 | ||
| Liver cirrhosis (yes vs. no) | 0.528 (0.208-1.341) | 0.179 | ||
| Platelet count (×109/L) | 0.998 (0.992-1.004) | 0.607 | ||
| Prothrombin time, INR | 0.212 (0.023-1.982) | 0.174 | ||
| Albumin (g/dL) | 1.025 (0.540-1.944) | 0.941 | ||
| Bilirubin (mg/dL) | 0.822 (0.630-1.071) | 0.147 | ||
| ALT (IU/L) | 1.000 (0.998-1.001) | 0.560 | ||
| Creatinine (mg/dL) | 0.427 (0.045-4.034) | 0.458 | ||
| HBeAg (positive vs. negative) | 2.315 (0.980-5.470) | 0.056 | 1.791 (0.703-4.564) | 0.222 |
| HBV DNA (log10 IU/mL) | 1.399 (0.982-1.992) | 0.063 | 1.022 (0.671-1.557) | 0.920 |
| Duration of treatment (months) | 0.997 (0.975-1.021) | 0.828 | ||
| Time to HBeAg loss (months) | 0.983 (0.945-1.022) | 0.381 | ||
| HBeAg seroconversion (yes vs. no) | 0.981 (0.314-3.070) | 0.974 | ||
| Duration of consolidation treatment (months) | 0.995 (0.968-1.022) | 0.721 | ||
| End-of-treatment HBsAg level (log10 IU/mL) | 2.606 (1.278-5.311) | 0.008 | 2.251 (1.076-4.706) | 0.031 |
HR, hazard ratio; CI, confidence interval; BMI, body mass index; INR, international normalized ratio; ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus, HBsAg, hepatitis B surface antigen.